To evaluate incidence and severity of adverse events (AEs), secondary to vaccination, in patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Spondyloarthritis (SpA), immune-mediated diseases treated with immunomodulating drugs, by administering a questionnaire
Latest Information Update: 29 Jun 2022
At a glance
- Drugs AZD 1222 (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
Most Recent Events
- 29 Jun 2022 New trial record
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism